Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity
Published version of a preprint
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The unfolded protein response (UPR) is a signal transduction pathway that coordinates cellular adaptation to microenvironmental stresses that include hypoxia, nutrient deprivation, and change in redox status. These stress stimuli are common in many tumors and thus targeting components of the UPR signaling is an attractive therapeutic approach. We have identified a first-in-class, small molecule inhibitor of the eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) or PERK, one of the three mediators of UPR signaling. GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC(50) of 0.9 nmol/L. It is highly selective for PERK with IC(50) values >100 nmol/L against a panel of 300 kinases. GSK2656157 inhibits PERK activity in cells with an IC(50) in the range of 10-30 nmol/L as shown by inhibition of stress-induced PERK autophosphorylation, eIF2α substrate phosphorylation, together with corresponding decreases in ATF4 and CAAT/enhancer binding protein homologous protein (CHOP) in multiple cell lines. Oral administration of GSK2656157 to mice shows a dose- and time-dependent pharmacodynamic response in pancreas as measured by PERK autophosphorylation. Twice daily dosing of GSK2656157 results in dose-dependent inhibition of multiple human tumor xenografts growth in mice. Altered amino acid metabolism, decreased blood vessel density, and vascular perfusion are potential mechanisms for the observed antitumor effect. However, despite its antitumor activity, given the on-target pharmacologic effects of PERK inhibition on pancreatic function, development of any PERK inhibitor in human subjects would need to be cautiously pursued in cancer patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, PERK inhibitors GSK2606414 and GSK2656157 possess antitumor activity and can reactivate T cell function in the TME in mouse embryonic fibroblasts; however, these compounds had adverse effects in mouse models, hindering their progress toward clinical trials [190, 191, 192, 193].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [191]
In the citing paper
“Similarly, PERK inhibitors GSK2606414 and GSK2656157 possess antitumor activity and can reactivate T cell function in the TME in mouse embryonic fibroblasts; however, these compounds had adverse effects in mouse models, hindering their progress toward clinical trials [190, 191, 192, 193].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [191]
Citations
Cites
Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase
Harding, H. P., Zhang, Y., & Ron, D. (1999) · Nature · doi:10.1038/16729 · Cited by 3,310 · cited 1×
“Wolcott–Rallison syndrome patients and PERK / knockout mice exhibit permanent neonatal or early-infancy insulindependent diabetes (15, 31, 33).”
BackgroundLee, A.-H., Iwakoshi, N. N., & Glimcher, L. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7448-7459.2003 · Cited by 2,037 · cited 1×
“The latter data suggests that IRE1 or ATF6 activation under ER stress may regulate the expression of those genes, consistent with prior studies (35).”
ResultThe unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
Brown, J. M., & Giaccia, A. J. (1998) · PubMed · Cited by 1,748
Harding, H. P., Zeng, H., Zhang, Y., Jungries, R., Chung, P., Plesken, H., Sabatini, D. D., & Ron, D. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00264-7 · Cited by 1,217
Shi, Y., Vattem, K. M., Sood, R., An, J., Liang, J., Stramm, L., & Wek, R. C. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.12.7499 · Cited by 774
Cullinan, S. B., & Diehl, J. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314219200 · Cited by 744
ER stress‐regulated translation increases tolerance to extreme hypoxia and promotes tumor growth
Bi, M., Naczki, C., Koritzinsky, M., Fels, D., Blais, J., Hu, N., Harding, H., Novoa, I., Varia, M., Raleigh, J., et al. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600777 · Cited by 729 · cited 4×
“19 with earlier studies showing reduced growth of tumors lacking the PERK gene (17, 21).”
BackgroundInfluentialThe role of the unfolded protein response in tumour development: friend or foe?
Ma, Y., & Hendershot, L. M. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1505 · Cited by 710 · cited 1×
“Stress stimuli that activate UPR include hypoxia, nutrient deprivation, increased protein synthesis, disruption of protein glycosylation (glucose deprivation), decreased luminal endoplasmic reticulum calcium, or changes in endoplasmic reticulum redox status (2, 3).”
BackgroundBetulin Is a Potent Anti-Tumor Agent that Is Enhanced by Cholesterol
Mullauer, F. B., Kessler, J. H., & Medema, J. P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005361 · Cited by 688
Koumenis, C., Naczki, C., Koritzinsky, M., Rastani, S., Diehl, A., Sonenberg, N., Koromilas, A., & Wouters, B. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.21.7405-7416.2002 · Cited by 686 · cited 1×
“Consistent with this, mouse fibroblasts derived from PERK , XBP1 , and ATF4 mice and fibroblasts expressing mutant eIF2α show reduced clonogenic growth and increased apoptosis under hypoxic conditions in vitro and reduced growth in mice (21, 23-25).”
Background
Research works printed but not linked: 1
- Gales, 2012, PERK inhibitor induces pancreatic toxicity in rats, Soc Tox Path
Cited by
The integrated stress response
Pakos‐Zebrucka, K., Koryga, I., Mnich, K., Ljujic, M., Samali, A., & Gorman, A. M. (2016) · The EMBO Reports · doi:10.15252/embr.201642195 · Cited by 2,659
“…[ 221 ], and CCT 020312 [ 216 ], or prevented using indirubin-3 0 -monoxime, SP 600125 , and SyK to inhibit GSK 2 [ 244 ], GSK 2606414 and GSK 2656157 to block PERK activation [ 240 , 254 ], C 16 and 2 -aminopurine to modulate PKR [ 242 , 255 ], and aminopyrazolindane to inhibit HRI [ 243 ].”
The Role of Endoplasmic Reticulum Stress in Human Pathology
Oakes, S. A., & Papa, F. R. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104649 · Cited by 1,581
Endoplasmic Reticulum Stress and Oxidative Stress in Cell Fate Decision and Human Disease
Cao, S. S., & Kaufman, R. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2014.5851 · Cited by 1,363
“Recently, a novel PERK kinase inhibitor (GSK2656157) was shown to inhibit the growth of tumor xenografts in mice (3).”
BackgroundEndoplasmic reticulum stress signals in the tumour and its microenvironment
Chen, X., & Cubillos-Ruiz, J. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00312-2 · Cited by 1,356
The impact of the endoplasmic reticulum protein-folding environment on cancer development
Wang, M., & Kaufman, R. J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3800 · Cited by 1,112
Metadata
- Authors
- Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., Choudhry, A. E., Alsaid, H., Jucker, B. M., Axten, J. M., & Kumar, R.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Authors' Affiliations: 1GlaxoSmithKline, Oncology R&D; 2Platform Technology & Science, Collegeville, Pennsylvania; 3Platform Technology & Science, Research Triangle Park, North Carolina; and 4Preclinical and Translational Imaging, LAS, King of Prussia, Pennsylvania
- Venue
- Cancer Research
- Published
- 2013-03-14
- Volume
- 73
- Issue
- 6
- Pages
- 1993-2002
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W1991250346
- Cited by
- 443
- References
- 44
- Citations by year
- 2026: 16 · 2025: 25 · 2024: 27 · 2023: 29 · 2022: 36 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 40 · 2017: 34 · 2016: 29 · 2015: 34 · 2014: 32 · 2013: 14
- FWCI
- 21.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- GSK2656157, unfolded protein response, PERK, eIF2α phosphorylation, ATF4, CHOP, anticancer activity, antiangiogenic activity, tumor xenografts, pancreatic function, amino acid metabolism, blood vessel density, vascular perfusion, kinase selectivity
- MeSH terms
- Adenine, Animals, Antineoplastic Agents, Female, Indoles, eIF-2 Kinase, Angiogenesis Inhibitors, Gene Expression Profiling, Protein Kinase Inhibitors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity. https://app.cochat.ai/papers/10.1158/0008-5472.can-12-3109
- The paper
- Atkins, C., Liu, Q., Minthorn, E., Zhang, S.-Y., Figueroa, D. J., Moss, K., Stanley, T. B., Sanders, B., Goetz, A., Gaul, N., Choudhry, A. E., Alsaid, H., Jucker, B. M., Axten, J. M., & Kumar, R. (2013). Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity. Cancer Research. https://doi.org/10.1158/0008-5472.can-12-3109
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.